SOUTH SAN FRANCISCO, Calif. & HEIDELBERG, Germany, June 03, 2026--Mission Bio, a leader in single-cell multiomics, jointly ...

Complete disruption of the CXCR4 chemokine receptor gene is embryologically lethal in mice, 11, 12 impeding direct study of CXCR4-mediated tumor progression and metastasis. Current approaches to study ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

WHIM syndrome (characterized by warts, hypogammaglobulinemia, infections, and myelokathexis) is a rare immunodeficiency caused by inherited autosomal-dominant mutations in CXCR4 that confer gain of ...

Treating breast cancer remains a major medical challenge worldwide. This is largely due to the ability of breast cancer cells ...

Immune cells play a key role during pregnancy, adjusting immune system response in a way that enables the fetus to develop while also protecting the parent and fetus from outside assaults like viruses ...

Effect of adjuvant treatment on the circulating CK-19 mRNA-positive tumor cells in patients with early stage breast cancer This is an ASCO Meeting Abstract from the 2006 ASCO Annual Meeting. This ...

KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high ...

The FDA approved mavorixafor (Xolremdi) capsules as the first therapy specifically for WHIM syndrome, a rare primary immunodeficiency and chronic neutropenic disorder, X4 Pharmaceuticals announced on ...

ALX40-4C NPS Allelix Terminated (Phase I/II) HIV No apparent effect was observed on viral load AMD3100 AnorMED Terminated (Phase I/II) HIV Little effect was observed on viral load AMD3100 (plerixafor) ...